Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY3375968 Alone and With Pembrolizumab in Advanced Solid Tumors
NCT05537740Phase 1Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2022
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of lanerkitug in solid tumor (4 arms), sponsored by Bayer. Primary endpoints: Number of participants with treatment-emergent adverse events, Maximum tolerated dose or Maximum administered dose up to 21 days and 4 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
lanerkitug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05537740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537740.